Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP,Chief Med Offr,Head of Dev | September 09, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 18,748 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Sale · Disposed 6,249 · Balance 18,748 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 10, 2026 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 6,249 | $64.57 | $403,497.93 |
DisclosureSEC source: 0002080176-26-000006 · wk-form4_1789072637.xml · nonDerivative · entry 1 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,748 Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 51,172 | $0.00 | $0.00 |
DisclosureSEC source: 0002080176-26-000004 · wk-form4_1785874216.xml · derivative · entry 3 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,519 Underlying: Common Stock, $0.10 par value · 51,172 shares Expires 2029-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted share units will vest in four equal annual installments on the first, second, third, and fourth anniversaries of the grant date. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 26,175 | $65.31 | $1,709,489.25 |
DisclosureSEC source: 0002080176-26-000004 · wk-form4_1785874216.xml · nonDerivative · entry 2 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,997 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 51,172 | $0.00 | $0.00 |
DisclosureSEC source: 0002080176-26-000004 · wk-form4_1785874216.xml · nonDerivative · entry 1 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted share units will vest in four equal annual installments on the first, second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 39,184 | $0.00 | $0.00 |
DisclosureSEC source: 0002080176-26-000002 · wk-form4_1773346981.xml · derivative · entry 2 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,184 Underlying: Common Stock, $0.10 par value · 39,184 shares Expires 2029-03-10 F3 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. F3 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 26,122 | $0.00 | $0.00 |
DisclosureSEC source: 0002080176-26-000002 · wk-form4_1773346981.xml · derivative · entry 1 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,122 Underlying: Common Stock, $0.10 par value · 26,122 shares Expires 2029-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F2 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 22:16 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 204,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000140 · wk-form4_1754432205.xml · derivative · entry 1 Massacesi Cristian · CIK 0002080176 · EVP,Chief Med Offr,Head of Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,691 Underlying: Common Stock, $0.10 par value · 204,691 shares Expires 2029-08-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted share units will vest in four equal annual installments on the first, second, third, and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.